Nutriband Inc. (NTRBW) 股票分析

公司概述

Nutriband Inc. (NTRBW) is engaged in the development of a portfolio of transdermal pharmaceutical products specifically for the United States market. The company's primary focus is on creating extended-release formulations, with its lead product in development being AVERSA fentanyl, an abuse deterrent fentanyl transdermal system designed to provide clinicians and patients with an extended-release transdermal fentanyl product. Although the specific sector and industry classifications are not publicly disclosed in the available data, the enterprise operates within the specialized pharmaceutical manufacturing landscape, targeting a niche segment of pain management solutions. The company's current market capitalization is not disclosed, and it reported annual revenue of $2.28 million over the trailing twelve months, while the number of employees is also unavailable. These financial figures indicate that the company operates on a micro-cap scale with limited revenue generation relative to the broader pharmaceutical industry, suggesting a position in the early stages of commercialization or a highly specialized, low-volume production model where revenue figures alone do not fully capture the potential value of its pipeline assets.

财务健康

Nutriband Inc. reported a revenue of $2.28 million for the trailing twelve months, yet this revenue generated a net income of -$34,592,176, revealing a severe structural cost burden where expenses vastly exceed gross earnings. The company's EBITDA stands at -$9,029,840, further highlighting significant operational inefficiencies or high capital expenditures associated with its research and development efforts. Free cash flow is negative at -$2,588,350, indicating that the company is consuming cash reserves to fund its operations rather than generating surplus liquidity for debt repayment or shareholder returns. The gross margin sits at 33.5%, which suggests that the cost of goods sold is managed relatively well for a development-stage biotech firm, but the operating margin of -1121.3% and a profit margin of 0.0% demonstrate that operating expenses are disproportionately high relative to sales, a common characteristic of pre-commercial pharmaceutical entities. The balance sheet shows $5.31 million in cash against $258,025 in debt, resulting in a debt-to-equity ratio of 3.42, which implies a leveraged capital structure despite the low absolute level of debt owed. The current ratio is 7.53, a figure that indicates robust short-term liquidity and a strong ability to cover short-term obligations with current assets. However, the return on equity is -136.1% and the return on assets is -55.2%, metrics that reveal management is currently unable to generate positive returns on the capital deployed into the business, reflecting the inherent risks of developing new pharmaceutical products before market entry.

估值评估

The trailing P/E ratio and forward P/E ratio are not available due to the lack of positive earnings, which prevents traditional earnings-based valuation methods from being applied. The price-to-book ratio is 1.85, indicating that the market values the company's equity at a premium of 85% over its book value, potentially reflecting the intangible value of its intellectual property and pipeline assets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available, limiting the ability to assess value based on revenue multiples or enterprise value relative to cash flow. The stock has traded between a 52-week high of $4.50 and a 52-week low of $0.80, providing a trading range of $3.70. While the exact current price is not provided, the historical volatility suggests the asset is highly sensitive to market sentiment regarding its clinical trial outcomes. The beta value is 1.93, which signifies that the stock price is expected to be approximately 93% more volatile than the broader market, exposing investors to significant price swings during periods of market stress or sector-specific news.

Growth & Income

Nutriband Inc. experienced a revenue decline of 46.4% year-over-year, while earnings growth is not applicable due to negative net income. This negative revenue growth trajectory indicates a contraction in sales or a reduction in the commercial footprint of its products, contrasting with the typical growth expectations for pharmaceutical firms in development. As the company does not pay a dividend, with no dividend yield or payout ratio available, it retains all earnings for reinvestment into its R&D pipeline rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a lack of current cash distributions, relying entirely on future product approvals and commercial success to reverse the current financial trends.